福森药业(01652.HK)指必要时增产双黄连口服液 股价飙升53%曾见20元纪录高
近几个月为中港流感高峰期,且近期「武肺」疫情持续扩散,於2018年7月才以每股2.08元在港上市的领先品牌双黄连类感冒药制造商--福森药业(01652.HK)指必要时调整「双黄连口服液」产能 该股今早突破去年9月所创上市高位8元,最多飙升近2.5倍至20元上市新高遇阻,现造8.8元,急涨53%,一向薄弱成交激增至1,441万股,仅次於首挂日成交量,涉资1.44亿元。
福森就近期有媒体报导,集团主要产品之一「双黄连口服液」具有可抑制新型冠状病毒功效指出,目前集团尚未对此开展任何研究活动,亦未就有关功效作出任何声明及保证。不过,公司将密切监察新型冠状病毒及「双黄连口服液」市场需求的发展,并在必要时审视及调整「双黄连口服液」的产能,以满足市场需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.